0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Hyperuricemia Drugs Market Research Report 2023
Published Date: October 2023
|
Report Code: QYRE-Auto-10Z12465
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Hyperuricemia Drugs Market Research Report 2022
BUY CHAPTERS

Global Hyperuricemia Drugs Market Research Report 2023

Code: QYRE-Auto-10Z12465
Report
October 2023
Pages:88
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Hyperuricemia Drugs Market Size

According to new survey, global Hyperuricemia Drugs market is projected to reach US$ 4556.4 million in 2029, increasing from US$ 2140 million in 2022, with the CAGR of 11.4% during the period of 2023 to 2029.

Hyperuricemia Drugs Market

Hyperuricemia Drugs Market

Hyperuricemia is the type of condition wherein an excessive level of uric acid is produced in the blood. The level of uric acid in the blood is the balance between the breakdown of purines and the rate of uric acid excretion. The alteration in the uric acid level may cause hyperuricemia. High uric acid can result in serious diseases such as painful arthritis called gout.
Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hyperuricemia Drugs market research.
Globally, the number of patients with hyperuricemia and gout is increasing year by year. According to statistics, the number of patients with hyperuricemia and gout in the world will reach 930 million in 2020, and the number of patients with hyperuricemia and gout in the world will be in 1.03 billion people in 2022.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Hyperuricemia Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Scope of Hyperuricemia Drugs Market Report

Report Metric Details
Report Name Hyperuricemia Drugs Market
Accounted market size in 2022 US$ 2140 million
Forecasted market size in 2029 US$ 4556.4 million
CAGR 11.4%
Base Year 2022
Forecasted years 2023 - 2029
Segment by Type
  • NSAIDs
  • Xanthine Oxidase Inhibitor
  • Selective Uric Acid Reabsorption Inhibitor
  • Carbonic Anhydrase Inhibitor
  • Glucocorticoid
  • Other
Segment by Application
  • Gout
  • Renal Calculus
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Horizon Therapeutics plc, Takeda Pharmaceutical Company Ltd, Mylan NV, Novartis International AG, Regeneron Pharmaceuticals, Romeg Therapeutics, Teijin Pharma Ltd, Lannett Company, Inc, GSK Plc
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

FAQ for this report

How fast is Hyperuricemia Drugs Market growing?

Ans: The Hyperuricemia Drugs Market witnessing a CAGR of 11.4% during the forecast period 2023-2029.

What is the Hyperuricemia Drugs Market size in 2029?

Ans: The Hyperuricemia Drugs Market size in 2029 will be US$ 4556.4 million.

Who are the main players in the Hyperuricemia Drugs Market report?

Ans: The main players in the Hyperuricemia Drugs Market are Horizon Therapeutics plc, Takeda Pharmaceutical Company Ltd, Mylan NV, Novartis International AG, Regeneron Pharmaceuticals, Romeg Therapeutics, Teijin Pharma Ltd, Lannett Company, Inc, GSK Plc

What are the Application segmentation covered in the Hyperuricemia Drugs Market report?

Ans: The Applications covered in the Hyperuricemia Drugs Market report are Gout, Renal Calculus, Other

What are the Type segmentation covered in the Hyperuricemia Drugs Market report?

Ans: The Types covered in the Hyperuricemia Drugs Market report are NSAIDs, Xanthine Oxidase Inhibitor, Selective Uric Acid Reabsorption Inhibitor, Carbonic Anhydrase Inhibitor, Glucocorticoid, Other

1 Hyperuricemia Drugs Market Overview
1.1 Product Overview and Scope of Hyperuricemia Drugs
1.2 Hyperuricemia Drugs Segment by Type
1.2.1 Global Hyperuricemia Drugs Market Value Comparison by Type (2023-2029)
1.2.2 NSAIDs
1.2.3 Xanthine Oxidase Inhibitor
1.2.4 Selective Uric Acid Reabsorption Inhibitor
1.2.5 Carbonic Anhydrase Inhibitor
1.2.6 Glucocorticoid
1.2.7 Other
1.3 Hyperuricemia Drugs Segment by Application
1.3.1 Global Hyperuricemia Drugs Market Value by Application: (2023-2029)
1.3.2 Gout
1.3.3 Renal Calculus
1.3.4 Other
1.4 Global Hyperuricemia Drugs Market Size Estimates and Forecasts
1.4.1 Global Hyperuricemia Drugs Revenue 2018-2029
1.4.2 Global Hyperuricemia Drugs Sales 2018-2029
1.4.3 Global Hyperuricemia Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Hyperuricemia Drugs Market Competition by Manufacturers
2.1 Global Hyperuricemia Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Hyperuricemia Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Hyperuricemia Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Hyperuricemia Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Hyperuricemia Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Hyperuricemia Drugs, Product Type & Application
2.7 Hyperuricemia Drugs Market Competitive Situation and Trends
2.7.1 Hyperuricemia Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Hyperuricemia Drugs Players Market Share by Revenue
2.7.3 Global Hyperuricemia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Hyperuricemia Drugs Retrospective Market Scenario by Region
3.1 Global Hyperuricemia Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Hyperuricemia Drugs Global Hyperuricemia Drugs Sales by Region: 2018-2029
3.2.1 Global Hyperuricemia Drugs Sales by Region: 2018-2023
3.2.2 Global Hyperuricemia Drugs Sales by Region: 2024-2029
3.3 Global Hyperuricemia Drugs Global Hyperuricemia Drugs Revenue by Region: 2018-2029
3.3.1 Global Hyperuricemia Drugs Revenue by Region: 2018-2023
3.3.2 Global Hyperuricemia Drugs Revenue by Region: 2024-2029
3.4 North America Hyperuricemia Drugs Market Facts & Figures by Country
3.4.1 North America Hyperuricemia Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Hyperuricemia Drugs Sales by Country (2018-2029)
3.4.3 North America Hyperuricemia Drugs Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Hyperuricemia Drugs Market Facts & Figures by Country
3.5.1 Europe Hyperuricemia Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Hyperuricemia Drugs Sales by Country (2018-2029)
3.5.3 Europe Hyperuricemia Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hyperuricemia Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Hyperuricemia Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Hyperuricemia Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Hyperuricemia Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Hyperuricemia Drugs Market Facts & Figures by Country
3.7.1 Latin America Hyperuricemia Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Hyperuricemia Drugs Sales by Country (2018-2029)
3.7.3 Latin America Hyperuricemia Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Hyperuricemia Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Hyperuricemia Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Hyperuricemia Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Hyperuricemia Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Hyperuricemia Drugs Sales by Type (2018-2029)
4.1.1 Global Hyperuricemia Drugs Sales by Type (2018-2023)
4.1.2 Global Hyperuricemia Drugs Sales by Type (2024-2029)
4.1.3 Global Hyperuricemia Drugs Sales Market Share by Type (2018-2029)
4.2 Global Hyperuricemia Drugs Revenue by Type (2018-2029)
4.2.1 Global Hyperuricemia Drugs Revenue by Type (2018-2023)
4.2.2 Global Hyperuricemia Drugs Revenue by Type (2024-2029)
4.2.3 Global Hyperuricemia Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Hyperuricemia Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Hyperuricemia Drugs Sales by Application (2018-2029)
5.1.1 Global Hyperuricemia Drugs Sales by Application (2018-2023)
5.1.2 Global Hyperuricemia Drugs Sales by Application (2024-2029)
5.1.3 Global Hyperuricemia Drugs Sales Market Share by Application (2018-2029)
5.2 Global Hyperuricemia Drugs Revenue by Application (2018-2029)
5.2.1 Global Hyperuricemia Drugs Revenue by Application (2018-2023)
5.2.2 Global Hyperuricemia Drugs Revenue by Application (2024-2029)
5.2.3 Global Hyperuricemia Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Hyperuricemia Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Horizon Therapeutics plc
6.1.1 Horizon Therapeutics plc Corporation Information
6.1.2 Horizon Therapeutics plc Description and Business Overview
6.1.3 Horizon Therapeutics plc Hyperuricemia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Horizon Therapeutics plc Hyperuricemia Drugs Product Portfolio
6.1.5 Horizon Therapeutics plc Recent Developments/Updates
6.2 Takeda Pharmaceutical Company Ltd
6.2.1 Takeda Pharmaceutical Company Ltd Corporation Information
6.2.2 Takeda Pharmaceutical Company Ltd Description and Business Overview
6.2.3 Takeda Pharmaceutical Company Ltd Hyperuricemia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Takeda Pharmaceutical Company Ltd Hyperuricemia Drugs Product Portfolio
6.2.5 Takeda Pharmaceutical Company Ltd Recent Developments/Updates
6.3 Mylan NV
6.3.1 Mylan NV Corporation Information
6.3.2 Mylan NV Description and Business Overview
6.3.3 Mylan NV Hyperuricemia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Mylan NV Hyperuricemia Drugs Product Portfolio
6.3.5 Mylan NV Recent Developments/Updates
6.4 Novartis International AG
6.4.1 Novartis International AG Corporation Information
6.4.2 Novartis International AG Description and Business Overview
6.4.3 Novartis International AG Hyperuricemia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Novartis International AG Hyperuricemia Drugs Product Portfolio
6.4.5 Novartis International AG Recent Developments/Updates
6.5 Regeneron Pharmaceuticals
6.5.1 Regeneron Pharmaceuticals Corporation Information
6.5.2 Regeneron Pharmaceuticals Description and Business Overview
6.5.3 Regeneron Pharmaceuticals Hyperuricemia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Regeneron Pharmaceuticals Hyperuricemia Drugs Product Portfolio
6.5.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.6 Romeg Therapeutics
6.6.1 Romeg Therapeutics Corporation Information
6.6.2 Romeg Therapeutics Description and Business Overview
6.6.3 Romeg Therapeutics Hyperuricemia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Romeg Therapeutics Hyperuricemia Drugs Product Portfolio
6.6.5 Romeg Therapeutics Recent Developments/Updates
6.7 Teijin Pharma Ltd
6.6.1 Teijin Pharma Ltd Corporation Information
6.6.2 Teijin Pharma Ltd Description and Business Overview
6.6.3 Teijin Pharma Ltd Hyperuricemia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Teijin Pharma Ltd Hyperuricemia Drugs Product Portfolio
6.7.5 Teijin Pharma Ltd Recent Developments/Updates
6.8 Lannett Company, Inc
6.8.1 Lannett Company, Inc Corporation Information
6.8.2 Lannett Company, Inc Description and Business Overview
6.8.3 Lannett Company, Inc Hyperuricemia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Lannett Company, Inc Hyperuricemia Drugs Product Portfolio
6.8.5 Lannett Company, Inc Recent Developments/Updates
6.9 GSK Plc
6.9.1 GSK Plc Corporation Information
6.9.2 GSK Plc Description and Business Overview
6.9.3 GSK Plc Hyperuricemia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 GSK Plc Hyperuricemia Drugs Product Portfolio
6.9.5 GSK Plc Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hyperuricemia Drugs Industry Chain Analysis
7.2 Hyperuricemia Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hyperuricemia Drugs Production Mode & Process
7.4 Hyperuricemia Drugs Sales and Marketing
7.4.1 Hyperuricemia Drugs Sales Channels
7.4.2 Hyperuricemia Drugs Distributors
7.5 Hyperuricemia Drugs Customers
8 Hyperuricemia Drugs Market Dynamics
8.1 Hyperuricemia Drugs Industry Trends
8.2 Hyperuricemia Drugs Market Drivers
8.3 Hyperuricemia Drugs Market Challenges
8.4 Hyperuricemia Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
    Table 1. Global Hyperuricemia Drugs Market Value Comparison by Type (2023-2029) & (US$ Million)
    Table 2. Global Hyperuricemia Drugs Market Value Comparison by Application (2023-2029) & (US$ Million)
    Table 3. Global Hyperuricemia Drugs Market Competitive Situation by Manufacturers in 2022
    Table 4. Global Hyperuricemia Drugs Sales (K Units) of Key Manufacturers (2018-2023)
    Table 5. Global Hyperuricemia Drugs Sales Market Share by Manufacturers (2018-2023)
    Table 6. Global Hyperuricemia Drugs Revenue (US$ Million) by Manufacturers (2018-2023)
    Table 7. Global Hyperuricemia Drugs Revenue Share by Manufacturers (2018-2023)
    Table 8. Global Market Hyperuricemia Drugs Average Price (US$/Unit) of Key Manufacturers (2018-2023)
    Table 9. Global Key Players of Hyperuricemia Drugs, Industry Ranking, 2021 VS 2022 VS 2023
    Table 10. Global Key Manufacturers of Hyperuricemia Drugs, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Hyperuricemia Drugs, Product Type & Application
    Table 12. Global Key Manufacturers of Hyperuricemia Drugs, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Hyperuricemia Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hyperuricemia Drugs as of 2022)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Hyperuricemia Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 17. Global Hyperuricemia Drugs Sales by Region (2018-2023) & (K Units)
    Table 18. Global Hyperuricemia Drugs Sales Market Share by Region (2018-2023)
    Table 19. Global Hyperuricemia Drugs Sales by Region (2024-2029) & (K Units)
    Table 20. Global Hyperuricemia Drugs Sales Market Share by Region (2024-2029)
    Table 21. Global Hyperuricemia Drugs Revenue by Region (2018-2023) & (US$ Million)
    Table 22. Global Hyperuricemia Drugs Revenue Market Share by Region (2018-2023)
    Table 23. Global Hyperuricemia Drugs Revenue by Region (2024-2029) & (US$ Million)
    Table 24. Global Hyperuricemia Drugs Revenue Market Share by Region (2024-2029)
    Table 25. North America Hyperuricemia Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 26. North America Hyperuricemia Drugs Sales by Country (2018-2023) & (K Units)
    Table 27. North America Hyperuricemia Drugs Sales by Country (2024-2029) & (K Units)
    Table 28. North America Hyperuricemia Drugs Revenue by Country (2018-2023) & (US$ Million)
    Table 29. North America Hyperuricemia Drugs Revenue by Country (2024-2029) & (US$ Million)
    Table 30. Europe Hyperuricemia Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 31. Europe Hyperuricemia Drugs Sales by Country (2018-2023) & (K Units)
    Table 32. Europe Hyperuricemia Drugs Sales by Country (2024-2029) & (K Units)
    Table 33. Europe Hyperuricemia Drugs Revenue by Country (2018-2023) & (US$ Million)
    Table 34. Europe Hyperuricemia Drugs Revenue by Country (2024-2029) & (US$ Million)
    Table 35. Asia Pacific Hyperuricemia Drugs Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
    Table 36. Asia Pacific Hyperuricemia Drugs Sales by Region (2018-2023) & (K Units)
    Table 37. Asia Pacific Hyperuricemia Drugs Sales by Region (2024-2029) & (K Units)
    Table 38. Asia Pacific Hyperuricemia Drugs Revenue by Region (2018-2023) & (US$ Million)
    Table 39. Asia Pacific Hyperuricemia Drugs Revenue by Region (2024-2029) & (US$ Million)
    Table 40. Latin America Hyperuricemia Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 41. Latin America Hyperuricemia Drugs Sales by Country (2018-2023) & (K Units)
    Table 42. Latin America Hyperuricemia Drugs Sales by Country (2024-2029) & (K Units)
    Table 43. Latin America Hyperuricemia Drugs Revenue by Country (2018-2023) & (US$ Million)
    Table 44. Latin America Hyperuricemia Drugs Revenue by Country (2024-2029) & (US$ Million)
    Table 45. Middle East & Africa Hyperuricemia Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 46. Middle East & Africa Hyperuricemia Drugs Sales by Country (2018-2023) & (K Units)
    Table 47. Middle East & Africa Hyperuricemia Drugs Sales by Country (2024-2029) & (K Units)
    Table 48. Middle East & Africa Hyperuricemia Drugs Revenue by Country (2018-2023) & (US$ Million)
    Table 49. Middle East & Africa Hyperuricemia Drugs Revenue by Country (2024-2029) & (US$ Million)
    Table 50. Global Hyperuricemia Drugs Sales (K Units) by Type (2018-2023)
    Table 51. Global Hyperuricemia Drugs Sales (K Units) by Type (2024-2029)
    Table 52. Global Hyperuricemia Drugs Sales Market Share by Type (2018-2023)
    Table 53. Global Hyperuricemia Drugs Sales Market Share by Type (2024-2029)
    Table 54. Global Hyperuricemia Drugs Revenue (US$ Million) by Type (2018-2023)
    Table 55. Global Hyperuricemia Drugs Revenue (US$ Million) by Type (2024-2029)
    Table 56. Global Hyperuricemia Drugs Revenue Market Share by Type (2018-2023)
    Table 57. Global Hyperuricemia Drugs Revenue Market Share by Type (2024-2029)
    Table 58. Global Hyperuricemia Drugs Price (US$/Unit) by Type (2018-2023)
    Table 59. Global Hyperuricemia Drugs Price (US$/Unit) by Type (2024-2029)
    Table 60. Global Hyperuricemia Drugs Sales (K Units) by Application (2018-2023)
    Table 61. Global Hyperuricemia Drugs Sales (K Units) by Application (2024-2029)
    Table 62. Global Hyperuricemia Drugs Sales Market Share by Application (2018-2023)
    Table 63. Global Hyperuricemia Drugs Sales Market Share by Application (2024-2029)
    Table 64. Global Hyperuricemia Drugs Revenue (US$ Million) by Application (2018-2023)
    Table 65. Global Hyperuricemia Drugs Revenue (US$ Million) by Application (2024-2029)
    Table 66. Global Hyperuricemia Drugs Revenue Market Share by Application (2018-2023)
    Table 67. Global Hyperuricemia Drugs Revenue Market Share by Application (2024-2029)
    Table 68. Global Hyperuricemia Drugs Price (US$/Unit) by Application (2018-2023)
    Table 69. Global Hyperuricemia Drugs Price (US$/Unit) by Application (2024-2029)
    Table 70. Horizon Therapeutics plc Corporation Information
    Table 71. Horizon Therapeutics plc Description and Business Overview
    Table 72. Horizon Therapeutics plc Hyperuricemia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 73. Horizon Therapeutics plc Hyperuricemia Drugs Product
    Table 74. Horizon Therapeutics plc Recent Developments/Updates
    Table 75. Takeda Pharmaceutical Company Ltd Corporation Information
    Table 76. Takeda Pharmaceutical Company Ltd Description and Business Overview
    Table 77. Takeda Pharmaceutical Company Ltd Hyperuricemia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 78. Takeda Pharmaceutical Company Ltd Hyperuricemia Drugs Product
    Table 79. Takeda Pharmaceutical Company Ltd Recent Developments/Updates
    Table 80. Mylan NV Corporation Information
    Table 81. Mylan NV Description and Business Overview
    Table 82. Mylan NV Hyperuricemia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 83. Mylan NV Hyperuricemia Drugs Product
    Table 84. Mylan NV Recent Developments/Updates
    Table 85. Novartis International AG Corporation Information
    Table 86. Novartis International AG Description and Business Overview
    Table 87. Novartis International AG Hyperuricemia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 88. Novartis International AG Hyperuricemia Drugs Product
    Table 89. Novartis International AG Recent Developments/Updates
    Table 90. Regeneron Pharmaceuticals Corporation Information
    Table 91. Regeneron Pharmaceuticals Description and Business Overview
    Table 92. Regeneron Pharmaceuticals Hyperuricemia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 93. Regeneron Pharmaceuticals Hyperuricemia Drugs Product
    Table 94. Regeneron Pharmaceuticals Recent Developments/Updates
    Table 95. Romeg Therapeutics Corporation Information
    Table 96. Romeg Therapeutics Description and Business Overview
    Table 97. Romeg Therapeutics Hyperuricemia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 98. Romeg Therapeutics Hyperuricemia Drugs Product
    Table 99. Romeg Therapeutics Recent Developments/Updates
    Table 100. Teijin Pharma Ltd Corporation Information
    Table 101. Teijin Pharma Ltd Description and Business Overview
    Table 102. Teijin Pharma Ltd Hyperuricemia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 103. Teijin Pharma Ltd Hyperuricemia Drugs Product
    Table 104. Teijin Pharma Ltd Recent Developments/Updates
    Table 105. Lannett Company, Inc Corporation Information
    Table 106. Lannett Company, Inc Description and Business Overview
    Table 107. Lannett Company, Inc Hyperuricemia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 108. Lannett Company, Inc Hyperuricemia Drugs Product
    Table 109. Lannett Company, Inc Recent Developments/Updates
    Table 110. GSK Plc Corporation Information
    Table 111. GSK Plc Description and Business Overview
    Table 112. GSK Plc Hyperuricemia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 113. GSK Plc Hyperuricemia Drugs Product
    Table 114. GSK Plc Recent Developments/Updates
    Table 115. Key Raw Materials Lists
    Table 116. Raw Materials Key Suppliers Lists
    Table 117. Hyperuricemia Drugs Distributors List
    Table 118. Hyperuricemia Drugs Customers List
    Table 119. Hyperuricemia Drugs Market Trends
    Table 120. Hyperuricemia Drugs Market Drivers
    Table 121. Hyperuricemia Drugs Market Challenges
    Table 122. Hyperuricemia Drugs Market Restraints
    Table 123. Research Programs/Design for This Report
    Table 124. Key Data Information from Secondary Sources
    Table 125. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Hyperuricemia Drugs
    Figure 2. Global Hyperuricemia Drugs Market Value Comparison by Type (2023-2029) & (US$ Million)
    Figure 3. Global Hyperuricemia Drugs Market Share by Type in 2022 & 2029
    Figure 4. NSAIDs Product Picture
    Figure 5. Xanthine Oxidase Inhibitor Product Picture
    Figure 6. Selective Uric Acid Reabsorption Inhibitor Product Picture
    Figure 7. Carbonic Anhydrase Inhibitor Product Picture
    Figure 8. Glucocorticoid Product Picture
    Figure 9. Other Product Picture
    Figure 10. Global Hyperuricemia Drugs Market Value Comparison by Application (2023-2029) & (US$ Million)
    Figure 11. Global Hyperuricemia Drugs Market Share by Application in 2022 & 2029
    Figure 12. Gout
    Figure 13. Renal Calculus
    Figure 14. Other
    Figure 15. Global Hyperuricemia Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
    Figure 16. Global Hyperuricemia Drugs Market Size (2018-2029) & (US$ Million)
    Figure 17. Global Hyperuricemia Drugs Sales (2018-2029) & (K Units)
    Figure 18. Global Hyperuricemia Drugs Average Price (US$/Unit) & (2018-2029)
    Figure 19. Hyperuricemia Drugs Report Years Considered
    Figure 20. Hyperuricemia Drugs Sales Share by Manufacturers in 2022
    Figure 21. Global Hyperuricemia Drugs Revenue Share by Manufacturers in 2022
    Figure 22. The Global 5 and 10 Largest Hyperuricemia Drugs Players: Market Share by Revenue in 2022
    Figure 23. Hyperuricemia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
    Figure 24. Global Hyperuricemia Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Figure 25. North America Hyperuricemia Drugs Sales Market Share by Country (2018-2029)
    Figure 26. North America Hyperuricemia Drugs Revenue Market Share by Country (2018-2029)
    Figure 27. United States Hyperuricemia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 28. Canada Hyperuricemia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 29. Europe Hyperuricemia Drugs Sales Market Share by Country (2018-2029)
    Figure 30. Europe Hyperuricemia Drugs Revenue Market Share by Country (2018-2029)
    Figure 31. Germany Hyperuricemia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 32. France Hyperuricemia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 33. U.K. Hyperuricemia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 34. Italy Hyperuricemia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 35. Russia Hyperuricemia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 36. Asia Pacific Hyperuricemia Drugs Sales Market Share by Region (2018-2029)
    Figure 37. Asia Pacific Hyperuricemia Drugs Revenue Market Share by Region (2018-2029)
    Figure 38. China Hyperuricemia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 39. Japan Hyperuricemia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 40. South Korea Hyperuricemia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 41. India Hyperuricemia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 42. Australia Hyperuricemia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 43. China Taiwan Hyperuricemia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 44. Southeast Asia Hyperuricemia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 45. Latin America Hyperuricemia Drugs Sales Market Share by Country (2018-2029)
    Figure 46. Latin America Hyperuricemia Drugs Revenue Market Share by Country (2018-2029)
    Figure 47. Mexico Hyperuricemia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 48. Brazil Hyperuricemia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 49. Argentina Hyperuricemia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 50. Middle East & Africa Hyperuricemia Drugs Sales Market Share by Country (2018-2029)
    Figure 51. Middle East & Africa Hyperuricemia Drugs Revenue Market Share by Country (2018-2029)
    Figure 52. Turkey Hyperuricemia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 53. Saudi Arabia Hyperuricemia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 54. UAE Hyperuricemia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 55. Global Sales Market Share of Hyperuricemia Drugs by Type (2018-2029)
    Figure 56. Global Revenue Market Share of Hyperuricemia Drugs by Type (2018-2029)
    Figure 57. Global Hyperuricemia Drugs Price (US$/Unit) by Type (2018-2029)
    Figure 58. Global Sales Market Share of Hyperuricemia Drugs by Application (2018-2029)
    Figure 59. Global Revenue Market Share of Hyperuricemia Drugs by Application (2018-2029)
    Figure 60. Global Hyperuricemia Drugs Price (US$/Unit) by Application (2018-2029)
    Figure 61. Hyperuricemia Drugs Value Chain
    Figure 62. Hyperuricemia Drugs Production Process
    Figure 63. Channels of Distribution (Direct Vs Distribution)
    Figure 64. Distributors Profiles
    Figure 65. Bottom-up and Top-down Approaches for This Report
    Figure 66. Data Triangulation
    Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Accenture

SIMILAR REPORTS